

This Offering Document (the “Offering Document”) constitutes an offering of these securities only in those jurisdictions where they may be lawfully offered for sale and therein only by persons permitted to sell such securities and to those persons to whom they may be lawfully offered for sale. This Offering Document is not, and under no circumstances is to be construed as, a prospectus or advertisement or a public offering of these securities.

No securities regulatory authority or regulator has assessed the merits of these securities or reviewed this document. Any representation to the contrary is an offence. This Offering (as defined herein) may not be suitable for you and you should only invest in it if you are willing to risk the loss of your entire investment. In making this investment decision, you should seek the advice of a registered dealer.

The securities described in this offering document have not been registered under the United States Securities Act of 1933, as amended (the “U.S. Securities Act”), or the securities laws of any state of the United States, and may not be offered or sold within the United States except pursuant to an exemption from the registration requirements of the U.S. Securities Act and applicable securities laws of any state of the United States. This offering document does not constitute an offer to sell, or the solicitation of an offer to buy, any of the securities described herein within the United States. “United States” has the meaning ascribed to it in Regulation S under the U.S. Securities Act.

OFFERING DOCUMENT UNDER THE LISTED ISSUER FINANCING EXEMPTION

October 19, 2026



TEMPRAMED TECHNOLOGIES LTD.
(the “Issuer”, “TempraMed” or “we”)

SUBSCRIPTION PRICE \$0.50 PER UNIT

PART 1 SUMMARY OF OFFERING

What are we offering?

Offering:	The units (“Units”) of the Issuer will be offered by way of the “listed issuer financing” exemption under Part 5A of National Instrument 45-106 – <i>Prospectus Exemptions</i> (“NI 45-106”) as amended by Coordinated Blanket Order 45-935 – <i>Exemptions from Certain Conditions of the Listed Issuer Financing Exemption</i> (the “LIFE Exemption”) in all the provinces and territories of Canada with the exception of Québec (the “Selling Jurisdictions”), with each Unit being composed of one common share of the Issuer (a “Share”) and one common share purchase warrant (a “Warrant”). Each whole Warrant will be exercisable to acquire one additional Share (each a “Warrant Share”, and together with the Units, Shares and Warrants, the “Securities”) at an exercise
------------------	--

	price of \$1.00 for a period of 18 months following the Closing Date (as defined below).
Offering Price:	\$0.50 per Unit.
Offering Amount:	A maximum of 16,000,000 Units for maximum gross proceeds of up to \$8,000,000 (the “ Maximum Offering ” or the “ Offering ”). There is no minimum offering.
Finders:	The Offering is being made on a non-brokered basis. The Issuer may pay qualified arm’s-length finders (the “ Finders ”) a cash fee equal to 7% of the gross proceeds raised from purchasers introduced by them and issue to them that number of Shares (the “ Finder Shares ”) equal to 7% of the number of Units sold to such purchasers. Assuming the Maximum Offering, the cash fees would total \$560,000 and up to 1,120,000 Finder Shares would be issuable.
Closing Date:	The Offering may be completed in one or more closings and is expected to close on or about November 13, 2026, or such other date as may be determined by the Issuer (the “ Closing Date ”), such date being no later than 45 days from the date the Issuer issues a press release announcing the Offering. On each closing, Units will be issued against receipt of funds.
Exchange:	The Shares of the Issuer are listed on the Canadian Securities Exchange (the “ Exchange ” or the “ CSE ”) under the symbol “VIVI”, and also trade on the OTCQB Venture Market (“ OTC ”) under the symbol “TMPTF” and on the Frankfurt Stock Exchange (“ FSE ”) under the symbol “9DY”. The Warrants will not be listed on any stock exchange.
Last Closing Price:	On October 19, 2026, the last trading day completed prior to the date of this Offering Document, the closing price of the Shares on the CSE was C\$0.49, on the OTC was US\$0.3022 and on the FSE was €0.277.
Resale Restrictions:	The Units sold under the Offering to investors resident in Canada will not be subject to a hold period pursuant to applicable Canadian securities laws, pursuant to the LIFE Exemption.
Description of Shares:	The holders of Shares are entitled to receive notice of, attend and vote at all meetings of the shareholders of the Issuer, and each Share confers the right to one vote at all such meetings. Subject to any class of shares ranking in priority to the Shares, the holders of Shares are entitled to receive and participate rateably in any dividends declared by the board of directors of the Issuer. Subject to any class of shares ranking in priority to the Shares, in the event of the liquidation, dissolution or winding-up of the Issuer or other distribution of the assets of the Issuer among its shareholders for the purposes of winding up its affairs, the holders of the Shares are entitled to participate rateably in the distribution of the assets of the Issuer.
Description of Warrants:	Each Warrant will entitle the holder to acquire, subject to adjustment in certain circumstances, one Warrant Share at an exercise price of \$1.00, exercisable at any time on or before 5:00 p.m. (Toronto time) on the day that is 18 months following the Closing Date. The Warrants will be created and issued pursuant to the terms of a warrant indenture or warrant certificate (the “ Warrant Instrument ”) to be dated as of the Closing Date. The Warrant Instrument will provide for adjustment in the number of Warrant Shares issuable upon the exercise of the Warrants or the exercise price per Warrant Share upon the occurrence of certain customary events, and will

	<p>contain provisions designed to protect holders of the Warrants against dilution upon the happening of certain events.</p> <p>No fractional Warrant Shares will be issuable to any holder of Warrants upon the exercise thereof, and no cash or other consideration will be paid in lieu of fractional shares. The holding of Warrants will not make the holder thereof a shareholder of the Issuer or entitle such holder to any right or interest in respect of the Warrants except as expressly provided in the Warrant Instrument. Holders of Warrants will not have any voting or pre-emptive rights or any other rights of a holder of Shares.</p> <p>Except for Shares and Warrants issued to, or for the account or benefit of, persons within the United States or U.S. persons who are acquiring Units pursuant to the registration exemption in Rule 506(b) of Regulation D, which will be issued in each case in certificated form, no certificates evidencing the Shares and Warrants are expected to be issued pursuant to the Offering. Instead, the Shares and Warrants sold pursuant to the Offering are expected to be issued in electronic form to the Canadian Depository for Securities (“CDS”) or nominees thereof and deposited with CDS on the Closing Date.</p>
--	--

Investors who participate in this Offering are deemed to have acknowledged certain facts and agreements on which the Issuer is relying.

All references in this Offering Document to “dollars” or “\$” are to Canadian dollars, unless otherwise stated. References to “US\$” are to United States dollars. The Issuer’s financial statements are presented in United States dollars; amounts derived from them are identified as US\$ where they appear below.

General Information

No securities regulatory authority or regulator has assessed the merits of these securities or reviewed this document. Any representation to the contrary is an offence. This offering may not be suitable for you and you should only invest in it if you are willing to risk the loss of your entire investment. In making this investment decision, you should seek the advice of a registered dealer.

TempraMed Technologies Ltd. is conducting a listed issuer financing under section 5A.2 of National Instrument 45-106 – Prospectus Exemptions. In connection with this Offering, the Issuer represents the following is true:

- The Issuer has active operations and its principal asset is not cash, cash equivalents or its exchange listing.
- The Issuer has filed all periodic and timely disclosure documents that it is required to have filed.
- The Issuer is relying on the exemptions in Coordinated Blanket Order 45-935 - Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Order”) and is qualified to distribute securities in reliance on the exemptions included in the Order.
- The total dollar amount of this offering, in combination with the dollar amount of all other offerings made under the listed issuer financing exemption and under the Order in the 12 months immediately preceding the date of the news release announcing this offering, will not exceed \$25,000,000.

- **The Issuer will not close this Offering unless the Issuer reasonably believes it has raised sufficient funds to meet its business objectives and liquidity requirements for a period of 12 months following the distribution.**
- **The Issuer will not allocate the available funds from this Offering to an acquisition that is a significant acquisition or restructuring transaction under securities law or to any other transaction for which the Issuer seeks security holder approval.**

Cautionary Note Regarding Forward-Looking Statements

This Offering Document contains “forward-looking statements” or “forward-looking information” within the meaning of applicable securities legislation (collectively referred to herein as “**forward-looking statements**” or “**forward-looking information**”). Often, but not always, forward-looking statements can be identified by the use of words such as “plans”, “will”, “proposes”, “expects”, “estimates”, “intends”, “anticipates” or “believes”, or variations (including negative and grammatical variations) of such words and phrases or state that certain actions, events or results “may”, “could”, “would”, “might” or “will” be taken, occur or be achieved. All statements, other than statements of historical fact, that address activities, events or developments that the Issuer believes, expects or anticipates will or may occur in the future (including, without limitation, statements regarding any objectives and strategies of the Issuer) are forward-looking statements. Examples of such forward-looking statements in this Offering Document include the Issuer’s business plans and strategies; the Issuer’s expected product launches, including the refrigerated version of VIVI Med and the VIVI Box; the negotiation and completion of definitive distribution agreements following non-binding letters of intent; the receipt of regulatory clearances and registrations in the Issuer’s target markets; the Issuer’s working capital and anticipated future revenue, costs and expenses; the completion of the Offering and the number of Units sold; the payment of finder’s fees; obtaining all required stock exchange and other approvals in connection with the Offering; use of available funds, including the proceeds of the Offering and the costs of the Offering; business objectives and milestones; and adequacy of financial resources. These forward-looking statements reflect the current expectations, assumptions or beliefs of the Issuer based on information currently available to the Issuer.

Forward-looking information is based on the reasonable assumptions, estimates, analysis and opinions of management made in light of its experience and its perception of trends, current conditions and expected developments, as well as other factors that management believes to be relevant and reasonable in the circumstances at the date that such statements are made, but which may prove to be incorrect. The material factors and assumptions used to develop the forward-looking statements contained in this Offering Document include, without limitation, the completion and realization of the anticipated benefits of the Offering; the timing for completion, settlement and closing of the Offering; the speculative nature of an investment in the Issuer’s securities; the satisfaction of the conditions to closing of the Offering, including receipt in a timely manner of regulatory and other required approvals and clearances, including the approval of the Exchange; the Issuer’s ability to manufacture and supply its products from its facilities in Israel and the United States; the continued demand for the Issuer’s products among consumers, distributors, pharmacies and payors; the use of proceeds of the Offering; potential adverse effects on the market price of the Issuer’s securities resulting from a sale of a substantial amount of the Issuer’s securities; price volatility of the Issuer’s securities; treatment under governmental regulatory regimes; general business, economic, competitive, political and social uncertainties; anticipated costs and the Issuer’s ability to obtain additional financing on satisfactory terms; the timing and results of product development and regulatory programs; the timely receipt of required approvals, registrations and permits in the jurisdictions in which the Issuer’s products are sold; the Issuer’s ability to operate in a safe, efficient

and effective manner; and the Issuer's ability to obtain financing as and when required and on reasonable terms.

There can be no assurance that forward-looking statements will prove to be accurate, as actual results, performance or developments could differ materially from those anticipated in such statements. Although the Issuer believes that the assumptions inherent in the forward-looking statements are reasonable, forward-looking statements are not guarantees of future performance and accordingly undue reliance should not be put on such statements due to the inherent uncertainty therein. The factors identified above are not intended to represent a complete list of the factors that could affect the Issuer.

Forward-looking statements involve known and unknown risks, uncertainties and other factors which may cause the Issuer's actual results, performance or developments to be materially different from any future results, performance or developments expressed or implied by the forward-looking statements, and even if such actual results are realized or substantially realized, there can be no assurance that they will have the expected consequences to, or effects on, the Issuer. Prospective investors should carefully consider all information contained in this Offering Document including information contained in the section entitled "Cautionary Note Regarding Forward-Looking Statements", before deciding to purchase the Units. Additionally, purchasers should consider the risk factors set forth below, as well as risks described in the Issuer's filings that are available on the Issuer's SEDAR+ profile at www.sedarplus.ca, including the risk factors in the Issuer's final prospectus dated September 25, 2025.

Risks which may impact the forward-looking information contained in this Offering Document include but are not limited to: the Issuer's securities may experience price volatility and investors may lose all or part of their investment; the Issuer's limited operating history and history of losses, including an accumulated deficit of US\$32.8 million as at June 30, 2026, and negative operating cash flow; the existence of a material uncertainty that may cast significant doubt on the Issuer's ability to continue as a going concern; the Issuer's working capital deficiency and dependence on third-party financing; the Issuer's ability to obtain additional financing on satisfactory terms or at all; the non-binding nature of letters of intent with prospective distributors, including those in Saudi Arabia, Kuwait, Greece and Cyprus, and the possibility that definitive agreements are not concluded on the terms described or at all; the absence of minimum purchase commitments under certain distribution agreements, including the agreement with CenterWell Pharmacy, which may be terminated on 60 days' notice; the Issuer's dependence on a limited number of distributors and sales channels; the Issuer's ability to obtain and maintain regulatory clearances, registrations and approvals for its products in the United States, Israel, Latin America, the Middle East, Europe and other markets, including registrations that are the responsibility of third-party distributors; changes in medical device, pharmaceutical and consumer product regulation; the Issuer's ability to protect its intellectual property, including pending patent and design applications; competition from existing and new temperature-protection and insulin-storage solutions; product defects, product liability and recall risks; the Issuer's ability to scale manufacturing at its facilities in Israel and Florida and to manage inventory; reliance on third-party suppliers; the Issuer's ability to successfully commercialize new products, including VIVI Cap Smart, VIVI Med, a refrigerated version of VIVI Med and the VIVI Box; the Issuer's ability to develop and maintain its connected-device software and mobile application, including integrations with Apple Health and Google Fit, and to comply with applicable data privacy and health information laws; the reliance of the Issuer on marketing spending to drive sales and the uncertain outcome of marketing and reimbursement initiatives; the preliminary and unaudited nature of recent sales figures, which may be revised and may not be indicative of future results; the Issuer's operations being primarily located in Israel and the effects of ongoing regional conflict and geopolitical instability, including disruption to operations, personnel, suppliers and logistics; fluctuations in currency exchange rates, in particular between the U.S. dollar, the Canadian dollar and the Israeli shekel; potential contingent

obligations, including the contingent issuance of up to 8,000,000 Shares upon the achievement of certain performance milestones; dilution to existing shareholders resulting from the Offering and from the exercise of outstanding warrants, options and restricted share units; sales of a significant number of Shares in the public markets that could depress the share price; liquidity risk with respect to the Issuer's securities; risks associated with the Issuer's trading on multiple markets; risks arising from the Issuer's outstanding government grants and obligations to the Israel Innovation Authority; risks associated with evolving corporate governance and public disclosure regulations; departure of key personnel on whom the Issuer is reliant; global economic conditions, inflation and interest rate changes; and the potential impacts of changes in trade and tariff policies between the countries in which the Issuer manufactures and sells its products.

PART 2

SUMMARY DESCRIPTION OF BUSINESS

What Is Our Business?

TempraMed Technologies Ltd., through its wholly owned subsidiary TempraMed Israel Ltd. ("**TempraMed Israel**"), develops patent-protected technology designed to serve a broad range of medical and consumer products. The Issuer's primary business focus is making injectors and other containers for temperature-sensitive medications "smart" and temperature-protected. The technology is designed to keep medication within adequate storage temperatures without a power source or human intervention for years, with further technology in development to enable "smart" tracking of medication usage, dosing and other data.

The Issuer's product line includes **VIVI Cap** for insulin and GLP-1 pens, **VIVI Epi** for epinephrine auto-injectors, **VIVI Cap Smart** (a connected version of VIVI Cap with an optional mobile application and add-on cover for the existing installed base) and **VIVI Med**, launched in January 2026 for vials, biologics and other temperature-sensitive medications and supplies. To date the Issuer has sold more than 130,000 devices worldwide through business-to-business ("**B2B**") and direct-to-consumer ("**B2C**") channels. The Issuer's primary operations are located in Israel, while most of its sales activity is in the United States, and it has opened an additional manufacturing facility in Florida.

Recent Developments

The following is a brief summary of key developments involving or affecting the Issuer over the past 12 months:

- In November 2025, the Shares commenced trading on the Frankfurt Stock Exchange under the symbol "9DY".
- On November 26, 2025, the Issuer announced an exclusive distribution agreement with Guri A.A.O, a leading consumer health distributor in Israel.
- On December 2, 2025, the Issuer announced a definitive exclusive distribution agreement with Döfin Sağlık Ürünleri for the VIVI product line in Turkey.
- In early December 2025, the Issuer announced a distribution partnership with Salomo Executive, a Dutch healthcare logistics company, covering the Netherlands, Belgium and Luxembourg.
- On December 8, 2025, the Issuer announced a strategic agreement under which VIVI Cap and VIVI Epi are available through Maccabi Healthcare Services, Israel's second-largest health maintenance organization, serving over 2.8 million members.

- On December 10, 2025, the Issuer appointed Professor Dr. Lutz Heinemann, a diabetes researcher, to its Scientific Advisory Board.
- On December 15, 2025, the Issuer announced the grant of a South Korean patent covering its thermal-insulation technology.
- On December 17, 2025, the Issuer announced a new U.S. production facility in Florida to expand manufacturing capacity and serve B2B customers.
- On December 26, 2025, the Issuer launched VIVI Cap Smart, a digitally connected version of VIVI Cap with injection tracking, an optional mobile application and a subscription-based software model.
- On December 31, 2025, the Issuer announced an expanded distribution partnership and commercial order with a South Korean healthcare distributor.
- On January 6, 2026, the Issuer announced its first commercial order from its Israeli distributor and completion of the initial shipment, enabling entry into a national pharmacy network.
- On January 12, 2026, the Issuer closed a non-brokered private placement of 3,322,153 units at \$0.76 per unit for gross proceeds of \$2,524,836, each unit comprising one Share and one Share purchase warrant exercisable at \$1.00 until July 12, 2027 (the “**January 2026 Private Placement**”).
- On January 14, 2026, the Issuer announced a positive response from medical payors to its reimbursement model, which it described as delivering a significant return on investment for payor coverage.
- On January 23, 2026, the Issuer announced the commercial launch of VIVI Med, designed for vials, biologics, GLP-1 therapies, alternative epinephrine auto-injectors and temperature-sensitive glucose test strips.
- On February 2, 2026, the Issuer announced a strategic media partnership with Dr. Phil’s Envoy Media to accelerate market adoption in the United States.
- On February 6, 2026, the Issuer announced the launch of a national pharmacy roll-out in Israel, shipping products to Maccabi pharmacies, and on February 10, 2026, announced a partnership with Super-Pharm, Israel’s leading pharmacy chain, to commence a national product roll-out.
- On February 26, 2026, the Issuer announced that more than 275 clinicians on the FrontrowMD platform across the United States recommend VIVI Cap to patients.
- On March 11, 2026, the Issuer announced that its independently validated payor return-on-investment model for reimbursement was further supported by a scientific publication on the clinical and economic rationale for VIVI Cap.
- On March 24, 2026, the Issuer announced the grant of a Chinese patent covering key aspects of the VIVI Box multi-medication storage box.
- On March 30, 2026, the Issuer announced a letter of intent for a distribution agreement in Panama, expanding its Central American exposure.
- On April 7, 2026, the Issuer announced the grant of an additional Brazilian patent for the VIVI Box.
- On April 29, 2026, the Issuer announced that it had continued from British Columbia into Ontario under the *Business Corporations Act* (Ontario).
- On May 14, 2026, the Issuer announced the grant of an Indian design patent for VIVI Cap Smart.

- On May 22, 2026, the Issuer was featured on a national U.S. broadcast of the Dr. Phil Show highlighting the risk of temperature exposure for insulin and other medications.
- On June 4, 2026, the Issuer announced a three-year exclusive distribution framework in Brazil with Mobil Saúde Comercial Ltda, beginning with VIVI Cap. Exclusivity takes effect only after Mobil Saúde places and fully prepays its initial order, and the agreement includes annual minimum purchase commitments. Regulatory approvals required in Brazil may be delayed, conditioned or denied.
- On June 26, 2026, the Issuer announced a non-binding letter of intent (dated June 16, 2026) with Rawafed Health International Company, a healthcare distributor in the Kingdom of Saudi Arabia, providing a pathway to an exclusive distribution arrangement.
- On June 30, 2026, the Issuer announced an expanded, non-exclusive partnership with McKesson Medical-Surgical (agreement dated June 23, 2026) to distribute the full VIVI portfolio (VIVI Cap, VIVI Cap Smart, VIVI Epi and VIVI Med) through McKesson's North American B2B channels and affiliates. The agreement does not disclose minimum purchase commitments.
- On July 6, 2026, the Issuer announced a non-binding letter of intent dated June 30, 2026 with Elegir Trading, a Kuwaiti investment and marketing firm, for the exclusive distribution of the Issuer's products in Kuwait for three years, starting with VIVI Cap and subject to an annual minimum purchase commitment in the first year.
- On July 30, 2026, the Issuer announced that its Shares were approved for trading on the OTCQB Venture Market under the symbol "TMPTF" and had become eligible for electronic clearing and settlement through the Depository Trust Company, while continuing to trade on the CSE under "VIVI".
- On August 4, 2026, the Issuer announced a strategic partnership with Stealth Health to integrate VIVI products into its telemedicine platform for longevity and wellness patients.
- On August 18, 2026, the Issuer announced that it had executed a definitive exclusive distribution agreement with TEM Consulting International S.A. ("**TEM**") for Panama, targeting clinics and pharmacies.
- On August 20, 2026, the Issuer announced that Maccabi Healthcare Services had exercised a one-year extension of its agreement with the Issuer on existing terms, and that Nancy Goertzen had resigned as a director effective August 19, 2026.
- On August 25, 2026, the Issuer announced a definitive five-year distribution agreement with Black Olives Company in Saudi Arabia for a private-label VIVI Cap, including an initial order of 10,000 units and approximately US\$3.8 million of potential purchases over the term, subject to regulatory clearance.
- On August 26, 2026, the Issuer filed its unaudited interim condensed consolidated financial statements and management's discussion and analysis for the six months ended June 30, 2026, which include a going concern note.
- On September 1, 2026, the Issuer announced a non-binding letter of intent with CPO Greece for the exclusive distribution of VIVI products in Greece.
- On September 18, 2026, the Issuer announced preliminary, unaudited sales of approximately US\$522,000 for July 2026, a company record, and approximately US\$403,000 for August 2026, bringing sales for the eight months ended August 31, 2026 to approximately US\$2.07 million,

which exceeds the Issuer's full-year 2025 sales of approximately US\$1.8 million. These figures are subject to change on completion of the Issuer's financial statements for the period ended September 30, 2026.

- On September 23, 2026, the Issuer announced a distribution agreement dated August 25, 2026 with CenterWell Pharmacy, Inc., the pharmacy services brand of Humana Inc., for the distribution of VIVI Cap and VIVI Epi in the United States. The agreement does not contain minimum purchase commitments and may be terminated by either party on 60 days' notice.
- On September 23, 2026, the Issuer announced an amendment to its exclusive distribution agreement with TEM extending the territory from Panama to Argentina, Venezuela, Colombia and Costa Rica and adding VIVI Med to the covered products, together with an additional commercial order from TEM expected to be fulfilled by the end of September 2026.
- On September 29, 2026, the Issuer announced a non-binding letter of intent dated July 31, 2026 with CPO Cyprus for the exclusive distribution of VIVI Cap and VIVI Epi in Cyprus.
- On September 30, 2026, the Issuer closed a non-brokered private placement for gross proceeds of \$1,177,940, consisting of 1,155,880 units at \$0.50 per unit (each unit comprising one Share and one Share purchase warrant exercisable at \$1.00 until March 30, 2028) and \$600,000 principal amount of 10% unsecured convertible debentures maturing September 30, 2027 and convertible at \$0.50 per Share (the "**September 2026 Private Placement**").
- On October 5, 2026, the Issuer announced that the VIVI Cap Smart platform now connects with Apple Health and Google Fit.
- On October 8, 2026, the Issuer announced that its Mexican patent application for the VIVI Box multi-medication storage box had been granted, with protection running through October 24, 2039.

Material Facts

There are no material facts about the securities being distributed hereunder that have not been disclosed either in this Offering Document or in another document filed by the Issuer over the 12 months preceding the date of this Offering Document on the Issuer's profile at www.sedarplus.ca.

What are the business objectives that we expect to accomplish using the available funds?

The Issuer intends to use the net proceeds from the Offering to continue the commercialization of its products and to fund working capital. Assuming the Maximum Offering, the Issuer's priorities are to:

- Allocate \$370,000 to product development, intellectual property and regulatory activities, including development of multi-medication VIVI Box (planned for release toward year-end 2026 or the first quarter of 2027), continued development of the VIVI Cap Smart application, and patent prosecution and regulatory work in the Issuer's target markets.
- Allocate \$2,580,000 to marketing activities, including the expansion of the Issuer's U.S. B2B and B2C marketing and distributor support and a pilot for reimbursement of the Issuer's products.
- Allocate \$990,000 to working capital, general corporate and administrative costs and contingencies.

PART 3 USE OF AVAILABLE FUNDS

What will our available funds be upon the closing of the Offering?

		Assuming the Maximum Offering
A	Amounts to be raised by the Offering	\$8,000,000
B	Selling commissions and fees ⁽¹⁾	\$560,000
C	Estimated Offering costs (e.g., legal, filing and regulatory fees)	\$100,000
D	Net proceeds of Offering: $D = A - (B+C)$	\$7,340,000
E	Working capital as at most recent month end (deficiency) ⁽²⁾	(\$3,400,000)
F	Additional sources of funding ⁽³⁾	\$0
G	Total available funds: $G = D+E+F$	\$3,940,000

(1) See Part 4 “Fees and Commissions” below. Represents the cash fee of 7% of the gross proceeds of the Offering, assuming all Units are sold to purchasers introduced by Finders. Finder Shares are non-cash consideration and are not included.

(2) The working capital deficiency as at September 30, 2026 is an estimate of management; actual results may differ. See “Cautionary Note Regarding Forward-Looking Statements” section above.

(3) The Issuer has not assumed any additional sources of funding. The proceeds of the September 2026 Private Placement are reflected in the working capital deficiency in line E to the extent held at September 30, 2026.

How will we use the available funds?

The Issuer intends to use the available funds as follows:

Description of intended use of available funds listed in order of priority	Assuming the Maximum Offering
Product development, intellectual property and regulatory	\$370,000
Marketing activities, including pilot for reimbursement	\$2,580,000
Working capital, general corporate and administrative costs and contingencies	\$990,000
Total: Equal to G in the Use of Available Funds table	\$3,940,000

The above-noted allocation of capital and anticipated timing represents the Issuer’s current intentions based upon its present plans and business condition, which could change in the future as its plans and business conditions evolve. Although the Issuer intends to expend the proceeds from the Offering as set forth above, there may be circumstances where, for sound business reasons, a reallocation of funds may be deemed prudent or necessary and may vary materially from that set forth above, as the amounts actually allocated and spent will depend on a number of factors, including the Issuer’s ability to execute

on its business plan. The Issuer has a working capital deficiency as set out above and will require additional sources of capital to fund ongoing operational requirements and planned product development and commercialization. The Issuer cannot guarantee that it will attain or maintain positive cash flow status in the next 12 months. Investors should be aware that there is no assurance that the Issuer will be able to secure such additional funding on acceptable terms or at all, and failure to do so may materially adversely affect the Issuer's business and financial condition. See the "*Cautionary Note Regarding Forward-Looking Statements*" section above.

The most recent unaudited interim financial statements of the Issuer for the three and six months ended June 30, 2026 and 2025 included a going concern note. To continue as a going concern, the Issuer must generate sufficient operating cash flow to fund its operational and capital requirements or secure new funding. There can be no assurance that these initiatives will be successful. The Issuer has not yet achieved profitable operations, has a working capital deficit and has not yet generated positive cash flows from its operating activities, which may cast doubt on the Issuer's ability to continue as a going concern. The Offering is intended to permit the Issuer to continue to develop its business operations and is not expected to affect the decision to include a going concern note in the next annual financial statements of the Issuer.

How have we used the other funds we have raised in the past 12 months?

The Issuer has completed the following financings in the 12 months preceding the date of this Offering Document. The disclosed net amounts are expressed in Canadian dollars.

Previous Financing	Intended Use of Proceeds	Disclosed Net Amount	Used to Date	Variances and Impact
January 2026 non-brokered private placement	Expansion of products portfolio, additional manufacturing site, increased working capital, increase in marketing activities, and expanding the number of distributors globally.	\$2,348,097	The proceeds were used as intended.	There were no significant variances to the intended use of proceeds.
September 2026 non-brokered private placement	Working capital and marketing activities. (Gross proceeds of \$1,177,940, comprising \$577,940 of units and \$600,000 of convertible debentures, less \$40,456 of cash finder's fees.)	\$1,137,484	The proceeds were used as intended.	There were no significant variances to the intended use of proceeds.

PART 4 FEES AND COMMISSIONS

Who are the dealers or finders that we have engaged in connection with this offering, if any, and what are their fees?

Finders:	The Offering is being conducted on a non-brokered basis. The Issuer may engage qualified arm's-length Finders in connection with the Offering and may pay compensation to such Finders in accordance with the policies of the Exchange.
-----------------	---

Compensation Type:	Cash fee and Finder Shares.
Cash Fee:	7% of the gross proceeds raised from purchasers introduced to the Issuer by the Finders. Assuming the Maximum Offering and that all Units are sold to purchasers introduced by Finders, the cash fee would be \$560,000.
Finder Shares:	Shares equal to 7% of the number of Units sold to purchasers introduced to the Issuer by the Finders. Assuming the Maximum Offering and that all Units are sold to purchasers introduced by Finders, up to 1,120,000 Finder Shares would be issued.

PART 5 PURCHASERS' RIGHTS

Rights of action in the Event of a Misrepresentation.

If there is a misrepresentation in this Offering Document, you have a right

- a) to rescind your purchase of these securities with the Issuer, or
- b) to damages against the Issuer and may, in certain jurisdictions, have a statutory right to damages from other persons.

These rights are available to you whether or not you relied on the misrepresentation. However, there are various circumstances that limit your rights. In particular, your rights might be limited if you knew of the misrepresentation when you purchased the securities.

If you intend to rely on the rights described in paragraph (a) or (b) above, you must do so within strict time limitations.

You should refer to any applicable provisions of the securities legislation of your province or territory for the particulars of these rights or consult with a legal adviser.

PART 6 ADDITIONAL INFORMATION ABOUT THE ISSUER

Where can you find more information about us?

You can access the Issuer's continuous disclosure under its profile at www.sedarplus.ca, on the Exchange's website at www.thecse.com and at www.tempramed.com.

PART 7
DATE AND CERTIFICATE

Dated: October 19, 2026

This Offering Document, together with any document filed under Canadian securities legislation on or after October 19, 2025, contains disclosure of all material facts about the securities being distributed and does not contain a misrepresentation.

(signed) "Ron Nagar"

Ron Nagar
Chief Executive Officer

(signed) "Gabriel Kabazo"

Gabriel Kabazo
Chief Financial Officer